McGuff Pharmaceuticals - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsMcGuff Pharmaceuticals

McGuff Pharmaceuticals

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Ascor	Ascorbic acid	2017-10-02	2024-2033	Common cold , Constipation , Methemoglobinemia , Penetrating wounds , Tyrosinemias , Scurvy , Hypercholesterolemia , Hypophosphatemia , Hypertriglyceridemia , Peripheral vascular diseases , Dermatitis , Alcoholic neuropathy , Seizures , Vitamin a deficiency , Hypoparathyroidism , Inborn errors metabolism , Photosensitivity disorders , Thiamine deficiency , Folic acid deficiency , Rickets , Vitamin b 6 deficiency , Megaloblastic anemia , Vitamin b deficiency , Xerophthalmia , Wernicke encephalopathy , Beriberi , Night blindness , Riboflavin deficiency , Pellagra , Chronic kidney failure , Cardiovascular diseases , Psoriasis , Lung neoplasms , Crohn disease , Skin neoplasms , Familial hypophosphatemic rickets , Osteoporosis

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

,

overactive urinary bladder

,

urinary incontinence

,

urinary bladder diseases

,

,

Aglatimagene besadenovec

prostatic neoplasms

,

castration-resistant prostatic neoplasms

,

breast neoplasms

,

ovarian neoplasms

Sodium ascorbate

pharmacokinetics

,

non-small-cell lung carcinoma

,

,

prostatic neoplasms

,

castration-resistant prostatic neoplasms

,

pancreatic neoplasms

,

,

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use